Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers (Links to an external site)
FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE (Links to an external site)
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
Response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for the treatment of symptomatic Alzheimer’s disease (AD)
Update on the DIAN-TU-002 Primary Prevention Trial
Update to the 15 November 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) regarding the DIAN-TU-002 Primary Prevention Trial with Gantenerumab.
WashU, Eisai form drug discovery collaboration (Links to an external site)
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website. Roche, known as Genentech in the United States, and the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University in St. Louis have been evaluating gantenerumab in […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease (Links to an external site)
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
Response to the 14-November-2022 announcement regarding the results from the GRADUATE I and II AD studies found on Roche’s website
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE (Links to an external site)
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
Response to the 28 September 2022 announcement found on Eisai’s website.
Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease (Links to an external site)
Could drugs prevent Alzheimer’s? These trials aim to find out (Links to an external site)
Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)
First Subject Enrolled in Phase II/III Study of Eisai’s Anti-MTBR Tau Antibody E2814 for Dominantly Inherited Alzheimer’s Disease (DIAD), conducted by DIAN-TU (Links to an external site)
New Alzheimer’s prevention trial in young people (Links to an external site)
$11.5 million commitment supports new Alzheimer’s prevention clinical trial (Links to an external site)
New eligibility criteria for participation in Tau NexGen E2814: A requirement for participants to learn their genetic status prior to enrollment
The new Tau NexGen E2814 clinical trial planned for DIAN-TU will be launching at most sites in 2022. This new trial design will offer individuals who have a dominantly inherited Alzheimer’s disease (DIAD) mutation access to investigational drugs that target both amyloid and tau. All participants will receive the anti-amyloid drug and also be randomized […]
International Alzheimer’s clinical trial to test two drugs in combination (Links to an external site)
Global Incubator Seed Grants awarded (Links to an external site)
The Search for a Drug to End Alzheimer’s (Links to an external site)
Some antiamyloids remove target plaques from the brain, yet don’t seem to halt cognitive decline. Researchers are working to understand why.
Aiming at the Tangle’s Heart? DIAN-TU Trial to Torpedo Tau’s Core (Links to an external site)
Encouraging findings in Alzheimer’s prevention trial lead to the next phase (Links to an external site)
International Alzheimer’s clinical trial to test tau drugs (Links to an external site)
Bateman, Diamond, Hultgren named to National Academy of Inventors (Links to an external site)
School of Medicine scientists honored for innovation
Dementia First blood test to help diagnose Alzheimer’s goes on sale (Links to an external site)
Barch, Bateman elected to National Academy of Medicine (Links to an external site)
AAIC 2020, dallo studio DIAN-TU la terapia contro l’Alzheimer (Links to an external site)
Elixir Factor Podcast S2 Ep6: Dominantly Inherited Alzheimer’s Disease: A View From Within (Links to an external site)
Gantenerumab improved markers of disease in rare, inherited form of Alzheimer’s disease
Further analysis of data from an international trial of two investigational drugs in people in the early stages of a rare, inherited form of Alzheimer’s disease has demonstrated that one of the drugs had a positive impact on biomarkers of the disease. The study (ClinicalTrials.gov Identifier: NCT01760005) is a phase 2/3 trial led by Washington […]